Research Article
The Association of Thyrotropin and Autoimmune Thyroid Disease in Developing Papillary Thyroid Cancer
Table 3
Clinicohistopathological results of papillary thyroid cancer classified according to serum TSH level.
| | Result | Benign () | PTC () | value |
| | Gender, female (%) | 198 (82.2) | 112 (88.2) | 0.132 | | Age (years) | 46.1 ± 14.7 | 47.7 ± 12.7 | 0.280 | | BMI (kg/m2) | 23.7 ± 3.6 | 24.0 ± 4.0 | 0.561 | | TSH (mIU/L) | 0.96 ± 0.99 | 1.59 ± 0.97 | 0.000 | | TSH with group | | | 0.000 | | (i) Group 1 (0.017–0.14) | 77 (32.0) | 7 (5.5) | | (ii) Group 2 (0.14–1.04) | 70 (29.0) | 31 (24.4) | | (iii) Group 3 (1.04–1.92) | 53 (22.0) | 49 (38.4) | | (iv) Group 4 (1.92–4.52) | 41 (17.0) | 40 (31.5) | | FT4 (ng/dl) | 1.8 ± 1.4 | 1.3 ± 0.7 | 0.006 | | T4 (μg/dl) | 9.2 ± 9.2 | 7.9 ± 2.1 | 0.398 | | T3 (ng/dl) | 144.3 ± 84.4 | 111.9 ± 30.1 | 0.010 | | Anti-TPO Ab positive (%) | 52 (34.7) | 26 (31.3) | 0.607 | | Anti-Tg Ab positive (%) | 8 (14.8) | 11 (17.7) | 0.674 | | TRAb positive (%) | 65 (69.1) | 8 (29.6) | 0.000 | | MicroPTC (%) | | 30 (23.6) | | | Stage | 1 | 94 (74.0) | | | 2 | 7 (23.6) | | | 3 | 10 (7.9) | | | 4 | 16 (12.6) | | | LN metastasis (%) | | 37 (29.1) | | | Synchronous nonthyroidal malignancies or tumors (%) | | 16 (12.6) | |
|
|
PTC: papillary thyroid cancer; BMI: body mass index; TSH: thyroid-stimulating hormone; FT4: free thyroxine; T4: thyroxine; T3: triiodothyronine; anti-TPO Ab: thyroid peroxidase antibodies; anti-TG Ab: antithyroglobulin antibody; TRAb: TSH receptor antibody; HT: Hashimoto’s thyroiditis; microPTC: papillary thyroid microcarcinoma; LN: lymph node.
|
